Well this is more of a case of a trial being perceived poorly and a stock going down... and then the insider buys.>
So what is interesting is the faith in the compound-!
So I gave you the action that day and then the house's response which was fairly positive despite lowering their price targets.
Design Therapeutics price target lowered to $24 from $29 at RBC Capital 12/08 DSGN RBC Capital analyst Leonid Timashev lowered the firm's price target on Design Therapeutics to $24 from $29 and keeps an Outperform rating on the shares. The company's data in DT-216 in Friedreich's ataxia was "somewhat complex" but suggests the drug was well tolerated and has signals of activity that could pull through to protein changes in relevant tissues upon higher dosing and longer exposures, the analyst tells investors in a research note. Timashev adds however that with protein increases no longer expected from MAD, and mRNA changes in PMBCs potentially not representative, he sees a longer catalyst path to more substantially de-risk the DT-216 program for investors.
So it's a so so analysis that calls for higher doses that's always problematic if side effects show up...
However management feels differently it seems // perhaps less " complex " data will be releases shortly?
